Compare BigBearai Holdings Inc (BBAI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Johnson & Johnson — how do they compare? BigBearai Holdings Inc trades at $3.26 (market cap $1.60B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 391.3× BigBearai Holdings Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | JNJ | |
|---|---|---|
Market Cap | $1.60B | $626.09B |
Sector | Technology | Health |
52-Week High | $8.91 | $267.24 |
52-Week Low | $2.61 | $172.78 |
Enterprise Value | $1.30B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.26, up 0.93% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations, continuing negative profitability trends. Recent news highlights defense contract wins and generative AI platform expansion, while analyst consensus remains cautious with 75% hold ratings.
The outlook remains challenging with persistent losses and negative cash flow projections for 2026. Investment opportunity lies in defense AI specialization and backlog growth, but risks include execution challenges, high valuation multiples, and dependence on government contracts. The stock requires careful monitoring of profitability improvements.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
